Endstage Renal Disease Owing to Diabetic Nephropathy in Mississippi: An Examination of Factors Influencing Renal Survival in a Population Prone to Late Referral
- 1 May 2001
- journal article
- conference paper
- Published by SAGE Publications in Journal of Investigative Medicine
- Vol. 49 (3) , 284-291
- https://doi.org/10.2310/6650.2001.33974
Abstract
Background: Diabetic nephropathy (DN) is the leading cause of endstage renal disease (ESRD) in the United States. We reviewed our experience with DN as a cause of ESRD in a predominantly poor, African American (AA) population. Methods: Charts of patients who entered the ESRD program through the University of Mississippi Medical Center with a primary diagnosis of DN from 1993 through 1998 were reviewed for factors that may affect renal survival. Time from initial clinic visit to entry into the ESRD program, or time to ESRD (TTE), was the primary end point. Results: Five hundred sixty-two patients entered the ESRD program (85% AA), and 210 of them had DN as their primary ESRD diagnosis. DN accounted for 50.5% of ESRD cases among AA females, but for less than 20% among AA males. In contrast, hypertension was the ESRD diagnosis in 48% of AA males. Patients observed in our nephrology clinic were analyzed further (n=171). At presentation, patients had advanced disease (serum creatinine [Cr]=5.92 mg/dL), were hypertensive, obese, and not likely to be on an angiotensin-converting enzyme (ACE) inhibitor. Determinants of TTE in univariate analysis were race (AA did better), initial blood urea nitrogen and plasma serum Cr levels, starting an ACE inhibitor at the University of Mississippi Medical Center, and the level of mean arterial pressure (MAP) during the course of follow-up. On multivariate analysis only initial Cr and race remained significant. The 142 AA diabetics (111 female) were analyzed separately. The only significant sex difference was body mass index (female, 33.6 vs male, 28.4 kg/m2; P=0.0069), but females tended to have relatively shorter TTE and higher blood pressure (BP). Univariate and multivariate analyses revealed the same factors as above as determinants of TTE; however, among AAs, presenting on a calcium channel blocker was negatively correlated with TTE in univariate analysis. Among the entire cohort and the AAs, patients who had MAP between 100 and 110 mm Hg during the course of follow-up did better in terms of renal survival than those who fell outside of that range. Conclusions: We conclude that AA females in Mississippi are significantly more predisposed to DN as a cause of ESRD than are AA males. Patients with DN in our population had poor BP control, presented to nephrologists with advanced disease, and often were not on an ACE inhibitor. The optimal level of BP control and which BP agents are best for this population need to be determined.Keywords
This publication has 31 references indexed in Scilit:
- Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: A systematic overview of randomized placebo-controlled trialsAmerican Journal of Kidney Diseases, 2000
- A Community-Based Study of Explanatory Factors for the Excess Risk for Early Renal Function Decline in Blacks vs Whites With DiabetesArchives of internal medicine (1960), 1999
- Risk of End-stage Renal Disease in Diabetes MellitusJAMA, 1997
- Interleukin-1-induced cyclooxygenase 2 expression is suppressed by cyclosporin A in rat mesangial cellsKidney International, 1994
- The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic NephropathyNew England Journal of Medicine, 1993
- Long-Term Stabilizing Effect of Angiotensin-Converting Enzyme Inhibition on Plasma Creatinine and on Proteinuria in Normotensive Type II Diabetic PatientsAnnals of Internal Medicine, 1993
- Effect of Antihypertensive Therapy on the Kidney in Patients with Diabetes: A Meta-Regression AnalysisAnnals of Internal Medicine, 1993
- The Excess Incidence of Diabetic End-Stage Renal Disease Among BlacksJAMA, 1992
- EARLY AGGRESSIVE ANTIHYPERTENSIVE TREATMENT REDUCES RATE OF DECLINE IN KIDNEY FUNCTION IN DIABETIC NEPHROPATHYThe Lancet, 1983
- Long-term antihypertensive treatment inhibiting progression of diabetic nephropathyBMJ, 1982